Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | Outperform → Mkt Perform | William Blair | |
| 9/16/2024 | Sector Outperform | Scotiabank | |
| 7/26/2024 | $3.00 | Buy | Craig Hallum |
| 5/13/2024 | $2.80 | Buy | TD Cowen |
| 5/3/2024 | $3.00 | Buy | Lake Street |
| 11/17/2021 | $21.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
10-Q - BIODESIX INC (0001439725) (Filer)
8-K - BIODESIX INC (0001439725) (Filer)
S-8 - BIODESIX INC (0001439725) (Filer)
LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher's collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix Development Services offerings, including customizable options that enable the world's leading life sciences companies, biopharmaceutical, and medical research institutions with scientific, technological, and operational capabilities. As Thermo Fisher announced in July 2025, Biodesix was an instrumental partner in the vali
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. "We had strong second quarter performance with 12% revenue growth and 80% gross margins," said Scott Hutton, Chief Executive Officer. "Last quarter, we expanded our commercial
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. Canaccord Genuity 45th Annual Growth Conference Fireside Chat Date: Tuesday, August 12, 2025Fireside Chat Time: 4:30 PM ETLocation: Boston, MA The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at biodesix.com. About Biodesix Biodesix is
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo
Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. "We had strong second quarter performance with 12% revenue growth and 80% gross margins," said Scott Hutton, Chief Executive Officer. "Last quarter, we expanded our commercial
LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after t
Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. "Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top line revenue, improving operational efficiencies and leverage, and advancing our pipeline," said Sc
SC 13G/A - BIODESIX INC (0001439725) (Subject)
SC 13G - BIODESIX INC (0001439725) (Subject)
SC 13D/A - BIODESIX INC (0001439725) (Subject)
William Blair downgraded Biodesix from Outperform to Mkt Perform
Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform
Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00